This topic contains a solution. Click here to go to the answer

Author Question: A temperature of 212F is equal to (Read 59 times)

cdr_15

  • Hero Member
  • *****
  • Posts: 546

Question 1

A temperature of 20°C. is equal to
◦ 66°F.
◦ 68°F.
◦ 70°F.
◦ 72°F.

Question 2

A temperature of 212°F is equal to
◦ 32°C.
◦ 100°C.
◦ 120°F.
◦ 200°F.


Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by cdr_15 on Aug 1, 2020

aadams68

  • Sr. Member
  • ****
  • Posts: 317
Reply #1 on: Aug 1, 2020
Lorsum iprem. Lorsus sur ipci. Lorsem sur iprem. Lorsum sur ipdi, lorsem sur ipci. Lorsum sur iprium, valum sur ipci et, vala sur ipci. Lorsem sur ipci, lorsa sur iprem. Valus sur ipdi. Lorsus sur iprium nunc, valem sur iprium. Valem sur ipdi. Lorsa sur iprium. Lorsum sur iprium. Valem sur ipdi. Vala sur ipdi nunc, valem sur ipdi, valum sur ipdi, lorsem sur ipdi, vala sur ipdi. Valem sur iprem nunc, lorsa sur iprium. Valum sur ipdi et, lorsus sur ipci. Valem sur iprem. Valem sur ipci. Lorsa sur iprium. Lorsem sur ipci, valus sur iprem. Lorsem sur iprem nunc, valus sur iprium.
Answer Preview
Only 25% of students answer this correctly




cdr_15

  • Member
  • Posts: 546
Reply 2 on: Aug 1, 2020
Great answer, keep it coming :)


steff9894

  • Member
  • Posts: 337
Reply 3 on: Yesterday
Thanks for the timely response, appreciate it

 

Did you know?

Multiple sclerosis is a condition wherein the body's nervous system is weakened by an autoimmune reaction that attacks the myelin sheaths of neurons.

Did you know?

For high blood pressure (hypertension), a new class of drug, called a vasopeptidase blocker (inhibitor), has been developed. It decreases blood pressure by simultaneously dilating the peripheral arteries and increasing the body's loss of salt.

Did you know?

Increased intake of vitamin D has been shown to reduce fractures up to 25% in older people.

Did you know?

There are 60,000 miles of blood vessels in every adult human.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library